Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
22 hedge funds and large institutions have $4.71M invested in Amplify Treatments, Testing and Advancements ETF in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 5 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
8% less capital invested
Capital invested by funds: $5.14M → $4.71M (-$424K)
12% less funds holding
Funds holding: 25 → 22 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$269K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$129K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$65K |
| 4 |
LPL Financial
San Diego,
California
|
+$52.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$28.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$274K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$43K |
| 3 |
APA
American Portfolios Advisors
Holbrook,
New York
|
-$42.7K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$18.8K |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$5K |
GERM Hedge Fund Activity: Q3 2022 in Review
22 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q3 2022, worth a combined $4.71M — down 8.2% from $5.14M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GERM and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was Goldman Sachs, adding an estimated $269K. The largest seller was CAPTRUST Financial Advisors, exiting entirely with an estimated $274K sold.
- 22 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q3 2022, down from 25 in Q2 2022.
- Funds reported $4.71M of Amplify Treatments, Testing and Advancements ETF stock for Q3 2022, down 8.2% quarter-over-quarter.
- 2 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q3 2022 and 5 closed out, a net change of -3 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q3 2022 was Goldman Sachs, an estimated $269K added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q3 2022 was CAPTRUST Financial Advisors, an estimated $274K sold.
Based on aggregated 13F filings for Q3 2022.